| Drug General Information |
| Drug ID |
D0J5XZ
|
| Former ID |
DIB007251
|
| Drug Name |
VP004
|
| Drug Type |
Antibody
|
| Indication |
Substance dependence [ICD10:F10-F19]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
Indevus Pharmaceuticals
|
| Target and Pathway |
| Target(s) |
Kappa-type opioid receptor |
Target Info |
|
[2]
|
|---|
| Delta-type opioid receptor |
Target Info |
|
[2]
|
| Mu-type opioid receptor |
Target Info |
|
[2]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Enkephalin release
|
|
Opioid proenkephalin pathway
|
|
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
GPCR downstream signalingWP69:TCR Signaling Pathway
|
|
Opioid Signalling
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025668) |
|---|
| REF 2 | WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders. |
|---|
